Shringi Sharma1, Steve Caritis2, Gary Hankins3, Menachem Miodovnik4,5, Mary F Hebert6, Don Mattison7, Raman Venkataramanan8. 1. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA. shringisharma@yahoo.com. 2. Departments of Obstetrics, Gynecology and Reproductive Sciences, Magee-Women's Hospital, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. 3. Department of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX, USA. 4. Medstar Health Research Institute, Hyatsville, MD, USA. 5. Georgetown-Howards University Center for Clinical and Translational Science, Washington, DC, USA. 6. Department of Pharmacy and Obstetrics & Gynecology, University of Washington, Seattle, WA, USA. 7. McLaughlin Centre for Population Health Risk Assessment, University of Ottawa, and Risk Sciences International, Ottawa, ON, Canada. 8. Department of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
Abstract
AIMS: 17α-hydroxyprogesterone caproate (17-OHPC) reduces the rate of preterm birth in women with a prior preterm birth. Limited data exist on the pharmacokinetics (PK) of 17-OHPC or the plasma concentrations achieved during therapy. In this study, we evaluated the population PK of 17-OHPC in pregnant subjects with singleton gestation and also evaluated intrinsic and extrinsic factors that may potentially affect 17-OHPC PK in this patient population. METHODS: Sixty-one women with singleton pregnancies participated in this trial. Subjects received weekly intramuscular injections of 250 mg 17-OHPC in 1 ml castor oil from the time of enrolment (16 0/7 weeks - 20 6/7 weeks) up to 35 weeks gestation or until delivery. Blood samples were obtained between 24 and 28 weeks, between 32 and 35 weeks and over a 28-day period beyond the last injection. Maternal and/or cord blood were obtained at delivery. Data analysis was performed by nonlinear mixed effects modelling (NONMEM(®) ). RESULTS: The 17-OHPC PK were best described by a model with one maternal compartment and one fetal compartment, with first-order absorption and elimination from the maternal compartment. Maternal body weight was a significant covariate for both clearance (CL/F) and volume of distribution (Vmaternal /F). The final population mean estimates were: CL/F 1797 l/d, Vmaternal /F 32 610 l and mother to cord rate constant 0.005 day(-1) . This report describes for the first time the population PK of 17-OHPC in singleton pregnancy. CONCLUSIONS: The population PK study reported here represents the initial steps in understanding and optimizing 17-OHPC therapy for preventing preterm birth.
AIMS: 17α-hydroxyprogesterone caproate (17-OHPC) reduces the rate of preterm birth in women with a prior preterm birth. Limited data exist on the pharmacokinetics (PK) of 17-OHPC or the plasma concentrations achieved during therapy. In this study, we evaluated the population PK of 17-OHPC in pregnant subjects with singleton gestation and also evaluated intrinsic and extrinsic factors that may potentially affect 17-OHPC PK in this patient population. METHODS: Sixty-one women with singleton pregnancies participated in this trial. Subjects received weekly intramuscular injections of 250 mg 17-OHPC in 1 ml castor oil from the time of enrolment (16 0/7 weeks - 20 6/7 weeks) up to 35 weeks gestation or until delivery. Blood samples were obtained between 24 and 28 weeks, between 32 and 35 weeks and over a 28-day period beyond the last injection. Maternal and/or cord blood were obtained at delivery. Data analysis was performed by nonlinear mixed effects modelling (NONMEM(®) ). RESULTS: The 17-OHPC PK were best described by a model with one maternal compartment and one fetal compartment, with first-order absorption and elimination from the maternal compartment. Maternal body weight was a significant covariate for both clearance (CL/F) and volume of distribution (Vmaternal /F). The final population mean estimates were: CL/F 1797 l/d, Vmaternal /F 32 610 l and mother to cord rate constant 0.005 day(-1) . This report describes for the first time the population PK of 17-OHPC in singleton pregnancy. CONCLUSIONS: The population PK study reported here represents the initial steps in understanding and optimizing 17-OHPC therapy for preventing preterm birth.
Authors: Tracy A Manuck; Yinglei Lai; Paul J Meis; Mitchell P Dombrowski; Baha Sibai; Catherine Y Spong; Dwight J Rouse; Celeste P Durnwald; Steve N Caritis; Ronald J Wapner; Brian M Mercer; Susan M Ramin Journal: Am J Obstet Gynecol Date: 2011-04-08 Impact factor: 8.661
Authors: Joyce A Martin; Hsiang-Ching Kung; T J Mathews; Donna L Hoyert; Donna M Strobino; Bernard Guyer; Shae R Sutton Journal: Pediatrics Date: 2008-04 Impact factor: 7.124
Authors: Martha L Bustos; Steve N Caritis; Kathleen A Jablonski; Uma M Reddy; Yoram Sorokin; Tracy Manuck; Michael W Varner; Ronald J Wapner; Jay D Iams; Marshall W Carpenter; Alan M Peaceman; Brian M Mercer; Anthony Sciscione; Dwight J Rouse; Susan M Ramin Journal: Am J Obstet Gynecol Date: 2017-05-15 Impact factor: 8.661